
Beyond Immunotherapy: The Future of NF2-mutated Renal Cell Carcinoma
A new study reveals that NF2 inactivation in renal cell carcinoma drives an aggressive, immune-resistant phenotype. The findings suggest that standard immunotherapy may be ineffective for these patients, highlighting an urgent need for molecularly targeted alternatives.
By Yekedüz, Bian, Siegmund, Machaalani, El Masri, Saleh, Saad, Ascione, El Hajj Chehade, Steiner, Barrios, Berg, McGregor, Mantia, Ravi, Xu, Hirsch, Choueiri, Serzan



